Showing results (1-10 of 33) with videos related to
Sort By:
Pageof 4
Expert Review of Hematology|November 30, 2017
A spotlight on the management of complications associated with myeloproliferative neoplasms: a clinician's perspectiveGraeme Greenfield, Mary F McMullinClinical Medicine (London, England)|December 4, 2014
Update in the myeloproliferative neoplasmsClaire N Harrison, Mary F McMullinBritish Journal of Haematology|October 23, 2015
Management of polycythaemia vera: a critical review of current dataMary F McMullin, Bridget S Wilkins, Claire N HarrisonBritish Journal of Haematology|April 3, 2012
Janus kinase inhibition and its effect upon the therapeutic landscape for myelofibrosis: from palliation to cure?Claire Harrison, Srdan Verstovsek, Mary F McMullin, et al.The Ulster Medical Journal|September 15, 2007
Transformation of cytogenetically normal chronic myelomonocytic leukaemia to an acute myeloid leukaemia and the emergence of a novel +13, +15 double trisomy resulting in an adverse outcomePeter McGrattan, Mervyn Humphreys, Donald Hull, et al.Hemoglobin|July 30, 2011
A novel base change leading to Hb Vanderbilt [β89(F5)Ser→Arg, AGT>AGA]Matthew J Goodyer, Ezzat I Elhassadi, Melanie J Percy, et al.American Journal of Hematology|November 15, 2011
Environmental, lifestyle, and familial/ethnic factors associated with myeloproliferative neoplasmsLesley A Anderson, Andrew S Duncombe, Maria Hughes, et al.European Journal of Haematology|July 8, 2005
Acute intestinal obstruction due to intramural haemorrhage in small intestine in a patient with severe haemophilia A and inhibitorKhaled M A Ramadan, John P Lowry, Alan Wilkinson, et al.Experimental Hematology|September 30, 2019
Methylation age as a correlate for allele burden, disease status, and clinical response in myeloproliferative neoplasm patients treated with vorinostatSuzanne McPherson, Graeme Greenfield, Christen Andersen, et al.Cancer|February 23, 2007
A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatmentAlan K Burnett, Donald Milligan, Archie G Prentice, et al.Pageof 4